Colistin Dosing in Preterm Infants with AKI and Tracheobronchial Pneumonia
In a preterm infant with acute kidney injury and tracheobronchial pneumonia requiring colistin, use a reduced dose of 1.5 mg/kg every 36 hours based on the degree of renal impairment, with close monitoring of renal function and electrolytes every 48-72 hours.
Dosing Algorithm for Preterm Infants with AKI
The FDA-approved dosing for colistin must be adjusted for renal impairment 1. While standard pediatric dosing is 2.5-5 mg/kg/day divided into 2-4 doses 2, AKI necessitates significant dose reduction:
Dose Adjustment Based on Renal Function:
- Severe renal impairment (CrCl 10-29 mL/min): 1.5 mg/kg every 36 hours 1
- Moderate impairment (CrCl 30-49 mL/min): 2.5 mg/kg once daily or divided into 2 doses 1
- Mild impairment (CrCl 50-79 mL/min): 2.5-3.8 mg/kg divided into 2 doses 1
For preterm infants, calculating creatinine clearance is challenging, so clinical assessment of AKI severity using KDIGO staging should guide dosing decisions.
Critical Monitoring Requirements
Acute kidney injury during colistin treatment is one of the most important factors related to clinical failure and mortality 2. The evidence shows:
- 70% of neonates on colistin develop AKI, with 35% classified as "possible" colistin-induced nephrotoxicity 3
- Higher plasma colistin levels correlate with AKI development (median 2.09 mg/L in AKI vs 1.04 mg/L in non-AKI patients) 3
- Electrolyte disturbances are common: hypomagnesemia, hypokalemia, hypophosphatemia, and hyponatremia occur frequently 4, 5, 6
Monitoring Protocol:
- Serum creatinine: Every 48-72 hours minimum 2
- Electrolytes (Mg, K, Na, PO4): Every 48-72 hours with aggressive replacement 4, 5, 6
- Urine output: Continuous monitoring
- Therapeutic drug monitoring: Consider measuring steady-state colistin levels after 6th dose if available 3
Route of Administration Considerations
For tracheobronchial pneumonia specifically, consider adjunctive nebulized colistin (5 mg/kg every 12 hours) in addition to reduced-dose IV therapy 7, 8, 9. Recent evidence shows:
- Inhaled colistin achieves superior microbiological eradication compared to IV alone 8
- Comparable clinical efficacy with potentially lower systemic toxicity 8, 9
- Safe in preterm neonates without additional nephrotoxicity 7, 9
Combination Therapy
Colistin should be used in combination with at least one other agent to which the pathogen is susceptible 2. If no susceptible agent exists, combine with a carbapenem at the lowest MIC. However, avoid aminoglycosides in the setting of AKI as this significantly increases nephrotoxicity risk 6.
Critical Pitfalls to Avoid
Do not use standard pediatric dosing in AKI - this dramatically increases nephrotoxicity risk and mortality 2, 1, 3
Do not combine with other nephrotoxins (aminoglycosides, vancomycin) when possible - the combination significantly worsens AKI 6
Do not delay electrolyte replacement - at least 24% of infants require supplementation, particularly magnesium which drops significantly during therapy 4, 5
Do not continue therapy without monitoring - there is no consensus on timing of withdrawal in AKI, but clinicians must weigh benefits versus harms continuously 2
Treatment Duration and Outcomes
- Median treatment duration: 9-14 days in preterm infants 4, 10, 5
- Clinical success rate: 69-89% in very low birth weight infants 4, 10, 5
- Mortality: 19-33% in critically ill neonates, often related to underlying sepsis severity 10, 3, 6
- AKI reversibility: Most electrolyte disturbances and AKI are reversible in survivors 5
Alternative Considerations
If available and the pathogen is susceptible, strongly consider newer beta-lactam/beta-lactamase inhibitors (ceftazidime-avibactam, ceftolozane-tazobactam) as they show better cure rates with less nephrotoxicity risk compared to polymyxins 2. However, in the setting of established AKI with multidrug-resistant organisms, dose-adjusted colistin remains a viable option with careful monitoring 4, 10, 5.